237 related articles for article (PubMed ID: 16467077)
21. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
22. [Topics in mTOR pathway and its inhibitors].
Dreyer C; Sablin MP; Faivre S; Raymond E
Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
[TBL] [Abstract][Full Text] [Related]
23. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK; Yang X; Thor AD; Somasundaram K
Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
[TBL] [Abstract][Full Text] [Related]
24. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
25. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.
Goswami A; Ranganathan P; Rangnekar VM
Cancer Res; 2006 Mar; 66(6):2889-92. PubMed ID: 16540633
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K-Akt pathway in kidney cancer.
Park JY; Lin PY; Weiss RH
Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
[TBL] [Abstract][Full Text] [Related]
27. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
[TBL] [Abstract][Full Text] [Related]
28. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
29. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.
Bursavich MG; Brooijmans N; Feldberg L; Hollander I; Kim S; Lombardi S; Park K; Mallon R; Gilbert AM
Bioorg Med Chem Lett; 2010 Apr; 20(8):2586-90. PubMed ID: 20303263
[TBL] [Abstract][Full Text] [Related]
30. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
[TBL] [Abstract][Full Text] [Related]
31. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
32. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
33. Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Chen Y; Rodrik V; Foster DA
Oncogene; 2005 Jan; 24(4):672-9. PubMed ID: 15580312
[TBL] [Abstract][Full Text] [Related]
34. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Crowder RJ; Ellis MJ
Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
[TBL] [Abstract][Full Text] [Related]
35. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
36. [Targeting of the AKT-mTOR pathway in head and neck and lung cancer].
Vignot S; Haberer S; Besse B
Bull Cancer; 2009; 96 Suppl 1():S57-63. PubMed ID: 19433374
[TBL] [Abstract][Full Text] [Related]
37. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Dehnhardt CM; Venkatesan AM; Delos Santos E; Chen Z; Santos O; Ayral-Kaloustian S; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Chaudhary I; Yu K; Gibbons J; Abraham R; Mansour TS
J Med Chem; 2010 Jan; 53(2):798-810. PubMed ID: 19968288
[TBL] [Abstract][Full Text] [Related]
38. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
[TBL] [Abstract][Full Text] [Related]
39. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R
Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455
[TBL] [Abstract][Full Text] [Related]
40. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
